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Abstract
Purpose To externally validate the clinical utility of Chinese Prostate Cancer Consortium Risk Calculator (CPCC-RC) and 
Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator 3 (A-ERSPC-RC3) 
for prediction prostate cancer (PCa) and high-grade prostate cancer (HGPCa, Gleason Score ≥ 3 + 4) in both Chinese and 
European populations.
Materials and methods The Chinese clinical cohort, the European population-based screening cohort, and the European 
clinical cohort included 2,508, 3,616 and 617 prostate biopsy-naive men, respectively. The area under the receiver operating 
characteristic curve (AUC), calibration plot and decision curve analyses were applied in the analysis.
Results The CPCC-RC’s predictive ability for any PCa (AUC 0.77, 95% CI 0.75–0.79) was lower than the A-ERSPC-RC3 
(AUC 0.79, 95% CI 0.77–0.81) in the European screening cohort (p < 0.001), but similar for HGPCa (p = 0.24). The CPCC-
RC showed lower predictive accuracy for any PCa (AUC 0.65, 95% CI 0.61–0.70), but acceptable predictive accuracy for 
HGPCa (AUC 0.73, 95% CI 0.69–0.77) in the European clinical cohort. The A-ERSPC-RC3 showed an AUC of 0.74 (95% 
CI 0.72–0.76) in predicting any PCa, and a similar AUC of 0.74 (95% CI 0.72–0.76) in predicting HGPCa in Chinese cohort. 
In the Chinese population, decision curve analysis revealed a higher net benefit for CPCC-RC than A-ERSPC-RC3, while 
in the European screening and clinical cohorts, the net benefit was higher for A-ERSPC-RC3.
Conclusions The A-ERSPC-RC3 accurately predict the prostate biopsy in a contemporary Chinese multi-center clinical 
cohort. The CPCC-RC can predict accurately in a population-based screening cohort, but not in the European clinical cohort.
Keywords Prostate cancer · Biopsy · Risk calculators · Asian populations · Net benefit · Clinical prediction model · 
External validation
Introduction
Prostate cancer (PCa) is the most prevalent malignancy in 
male in western countries, and account for one-quarter of 
new malignancy diagnoses in men in the United States [1]. 
The PCa incidence is lower in Asian countries [2, 3]. This 
could be caused by racial differences and/or different screen-
ing strategies [4]. In western populations, PCa screening 
with a purely PSA based biopsy indication leads to unnec-
essary biopsies [5]. Would prostate cancer screening with a 
comparable PSA cut-off be applied in the Chinese popula-
tion it would likely lead to even more unnecessary biopsies, 
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giving the lower PCa detection rate at similar PSA levels in 
the Chinese population [6].
Risk calculators (RC) have been developed to aid physi-
cians in shared decision making before taking the actual 
prostate biopsy and have shown to reduce unnecessary 
biopsies by more than 30% [7]. However, the application of 
western-developed risk calculators in Asian countries might 
yield lower predictive performance. Recently published 
studies in Korean [8] and Chinese populations [9] showed 
that the Rotterdam European Randomized Study of Screen-
ing for Prostate Cancer Risk Calculator 3 (ERSPC-RC3) 
and Prostate Cancer Prevention Trial risk calculator (PCPT-
RC) overestimate the risk of PCa. Therefore, the develop-
ment of Asian-specific RCs for Asians including Chinese 
is desired. The Chinese Prostate Cancer Consortium Risk 
Calculator (CPCC-RC) was developed using multi-center 
clinical data from Chinese men to predict biopsy outcomes. 
This RC showed good predictive performance after exter-
nal validation [10]. Recently, the ERSPC-RC3 was adapted 
to the Asian setting, showing excellent discrimination and 
calibration in Hong Kong-based development and external 
validation cohorts [11].
In this study, we assessed the generalizability and clini-
cal usefulness of both the CPCC-RC and the Asian-adapted 
ERSPC-RC3 (A-ERSPC-RC3) by externally validating 
these RCs in a contemporary multi-center Chinese clini-
cal cohort and a multi-center European clinical cohort. In 
addition, considering the lower prevalence of PCa in Asia, 
we also evaluated the performance of the CPCC-RC in the 
ERSPC Rotterdam population-based screening cohort. All 
men included in this study were biopsy naive.
Methods
Study population
This study is approved by Ethical review board of Chang-
hai Hospital. The Chinese validation cohort included 2,508 
referred men from five hospitals who were enrolled from 
January 2010 to December 2013. These men were not 
included in the development cohort of the CPCC-RC [10]. 
Biopsy indication was PSA ≥ 4.0 ng/ml, abnormal digital 
rectal examination (DRE), or a suspicious lesion on transrec-
tal ultrasound (TRUS) imaging. They received 8–12 system-
atic TRUS-guided biopsy cores, with no targeted biopsies 
were performed. Patient’s characteristics were prospectively 
gathered; %freePSA (freePSA/total PSA) and prostate vol-
ume was missing in 116 and 33 men, respectively. Missing 
data were imputed using all variables which were used in 
the development of both models. Imputation was executed 
by Multivariate Imputation by Chained Equations (MICE) 
and was repeated five times [12].
The European screening cohort consists of 3616 men 
biopsied at the first round of screening in the Rotterdam 
ERSPC section from November 1993 to March 2000. 
Biopsy indication was PSA ≥ 3.0 ng/ml or abnormal DRE 
finding. All patients underwent lateral sextant biopsies and 
extra biopsies whether a hypo-echogenic lesion was found. 
Detailed characteristics of this study and data management 
have been described previously [5, 13]. This cohort is the 
development cohort of the original ERSPC-RC3.
The European clinical cohort consisted of 617 men 
from four different sites (Berlin, Münster, Paris, Rennes). 
Men were referred for further assessment based on a PSA 
≥ 4.0 ng/ml and/or suspicious DRE. These men were not a 
part of the development of the ERSPC-RCs. They received 
standard clinical health care at each participating site 
(≥ 10 cores transrectal ultrasound biopsies). Data on PSA, 
%freePSA, DRE, prostate volume and biopsy outcome were 
collected. Two men had no data on prostate volume and 
DRE finding; in these men the mean value of the prostate 
volume was used and DRE was set on normal.
Outcome measurements and prediction models
The primary endpoint was the presence of histologic adeno-
carcinoma on biopsy graded with Gleason score [14]. High-
grade (HG) PCa was defined as Gleason score ≥ 7, other 
prostate cancers were defined as low-grade prostate cancer 
(LGPCa) [15]. The A-ERSPC-RC3 was adjusted for the 
Asian setting by changing the intercept of the constant and 
was validated in more than 2000 Chinese men [16]. The 
A-ERSPC-RC3 includes PSA, TRUS measured prostate vol-
ume, DRE and TRUS abnormality. The CPCC-RC included 
PSA, TRUS measured prostate volume and DRE abnormal-
ity, but no TRUS abnormality, while age and %freePSA were 
included in the model.
Statistical analysis
Baseline characteristics of patients with PCa, LGPCa, and 
HGPCa were compared using the Mann–Whitney U test for 
continuous data and chi-square test for categorical data. For 
each risk calculator, the predicted probabilities for the pres-
ence of any PCa and HGPCa were calculated. The accuracy 
of the prediction models was assessed in each cohort by 
discrimination and calibration properties. The discrimina-
tive power of the prediction models for the presence of any 
PCa or HGPCa versus men without PCa was determined by 
the area under the receiver operating characteristic curve 
(AUC). Thousand bootstrap samples were created to test 
significance between the AUCs.
For calibration, the observed percentages of men with 
presences of PCa were plotted against the predicted prob-
ability of men having PCa after dividing the predicted 
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probabilities into deciles. For every decile, we calculated the 
95% CI of the observed percentage of responders. In addi-
tion, a histogram was made for the actual frequency of the 
predicted probabilities. The goodness-of-fit of the data to the 
predictions was evaluated by the Hosmer–Lemeshow test. 
Statistical analyses were performed in R statistical package, 
version 3.3.1. A p value < 0.05 was considered statistically 
significant.
Results
Comparison of patients’ characteristics
Men in the Chinese cohort had a median age of 69 years 
(IQR 63–75) and the median number of biopsy cores of 
10 (IQR 8–12). PCa was found in 857 (34%) men and 599 
(24%) men had HGPCa. In the European screening cohort 
and the clinical cohort, the median age was 64 years and 
65 years, respectively. PCa was present in 885 (25%) and 
290 (47%) men, while HGPCa was present in 313 (9%) and 
142 (23%) men, respectively. Furthermore, men from the 
Chinese cohort had a larger prostate volume and a higher 
PSA level (Table 1).
External validation in the European screening 
cohort
The CPCC-RC had slightly lower predictive ability for any 
prostate cancer (AUC 0.77, 95% CI 0.75–0.79) than the 
A-ERSPC-RC (AUC 0.79, 95% CI 0.77–0.81, p < 0.01). For 
HGPCa, similar predictive ability between the CPCC-RC 
(AUC 0.86, 95% CI 0.83–0.88) and the A-ERSPC-RC (AUC 
0.86, 95% CI 0.84–0.89, p = 0.24) was found (Table 2). Cali-
bration plots showed that the CPCC-RC would generally 
underestimate the risk of any PCa in the European screening 
cohort by 10–15%. However, the CPCC-RC showed good 
calibration for HGPCa, especially at lower risk thresholds 
(Fig. 1a, b). Decision curve analysis showed a higher net 
benefit for the CPCC-RC above the risk threshold of 7.5% 
for any PCa and 4% for HGPCa in comparison to a biopsy 
all scenario men, (Fig. 2a, b). Net-benefit for the A-ERSPC-
RC3 was even higher than the CPCC-RC.
External validation in the European clinical cohort
Validation of the CPCC-RC in the European clinical cohort 
had a moderate discriminative ability in predicting any PCa 
(AUC 0.65, 95% CI 0.61–0.70), and good discriminative 
ability in predicting HGPCa (AUC 0.73, 95% CI 0.69–0.77). 
The A-ERSPC-RC had a similar discrimination for any PCa 
(AUC 0.65, 95% CI 0.60–0.69, p = 0.79) and lower discrimi-
nation for HGPCa (AUC 0.69, 95% CI 0.65–0.73, p < 0.01). 
Calibration analyses showed that the CPCC-RC would gen-
erally underestimate the risk of both any PCa and HGPCa 
in the European clinical cohort (Fig. 1c, d). Decision curve 
analysis for any PCa and HGPCa showed no improvement in 
net benefit when using the CPCC-RC or the A-ERSPC-RC 
in the European clinical dataset (Fig. 2c, d).
External validation in the Chinese cohort
External validation of A-ERSPC-RC3 in the Chinese clini-
cal cohort showed an AUC of 0.74 (95% CI 0.72–0.76) in 
predicting any PCa, and a similar AUC of 0.74 (95% CI 
0.72–0.76) in predicting HGPCa. These AUC’s are sig-
nificantly lower than the AUC’s of the CPCC-RC (0.77, 
95% CI 0.74–0.77, p < 0.001) and 0.77 (95% CI 0.75–0.79, 
p < 0.001), respectively. Calibration plots showed that the 
A-ERSPC-RC3 underestimated the risk of any PCa in the 
risk range of 0–40% and overestimated the risk in the risk 
range over 60%. The CPCC-RC, on the contrary, underesti-
mated the risk of any PCa in higher risk ranges (30%-100%) 
but was well-calibrated in the risk range of 0–30% (Fig. 1e). 
Also for the prediction of HGPCa, the CPCC-RC was bet-
ter calibrated than the A-ERSPC-RC3 in most risk ranges. 
The A-ERSPC-RC3 underestimated the risk of HGPCa in 
the risk range of 0–40% and overestimated the risk in the 
risk range of 60–100% (Fig. 1f). Improvement in net benefit 
was found for the CPCC-RC at risks of 12.5% and above 
for any PCa and 8% or more for HGPCa (Fig. 2e, f). For 
the A-ERSPC-RC, an improvement in net benefit was found 
from a risk threshold of 20% onward for any PCa and 15% 
for HGPCa. Higher net benefit was found for the CPCC-
RC than for the A-ERSPC-RC3. At a 10% risk threshold 
for predicting HGPCa, the biopsy reduction is 25% for the 
CPCC-RC and 28% for A-ERSPC-RC. This threshold would 
result in missing 8% (CPCC-RC) and 10% (A-ERSPC-RC) 
of the HGPCa diagnoses (Table 3). The use of CPCC-RC 
would avoid an additional 6.8 biopsies per 1000 men at risk 
compared to the A-ERSPC-RC. At the 10% risk threshold 
the CPCC has a net benefit of 0.16. This implies that to avoid 
one unnecessary biopsy, without increasing the percentage 
of missed diagnoses of HGPCa, the CPCC-RC should be 
applied to six men.
Discussion
The A-ERSPC-RC3 which originated from the original 
ERSPC-RC can accurately predict the outcome of prostate 
biopsy in a contemporary Chinese multi-center clinical 
cohort [11]. However, the calibration plots showed an under-
estimation of the probability of detecting PCa on biopsy in 
the Chinese external validation cohort used in the current 
analyses. This underestimation is probably attributable to 
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Table 2  Area under the receiver 
operating characteristic curve 
for the Chinese Prostate Cancer 
Consortium Risk Calculator and 
the Asian adapted Rotterdam 
European Randomized Study of 
Screening for Prostate Cancer 
Risk Calculator 3 predicting 
any PCa or HGPCa in the three 
cohorts
PCa prostate cancer, HGPCa high-grade prostate cancer, EU European, CPCC-RC Chinese Prostate Can-
cer Consortium Risk Calculator, A-ERSPC-RC3 Asian adapted Rotterdam European Randomized Study of 
Screening for Prostate Cancer Risk Calculator 3
Cohort-RC Any PCa (95% CI) p value HGPCa (95% CI) p value
EU screening
 CPCC-RC 0.77 (0.75–0.79) 0.86 (0.83–0.88)
 A-ERSPC-RC3 0.79 (0.77–0.81) < 0.01 0.86 (0.84–0.89) 0.24
EU clinical
 CPCC-RC 0.65 (0.61–0.70) 0.73 (0.69–0.77)
 A-ERSPC-RC3 0.65 (0.60–0.69) 0.79 0.69 (0.65–0.73) < 0.01
Chinese
 CPCC-RC 0.77 (0.74–0.77) 0.77 (0.75–0.79)
 A-ERSPC-RC3 0.74 (0.72–0.76) < 0.01 0.74 (0.72–0.76) < 0.01
Fig. 1  Calibration plot for a predicting any prostate cancer in the 
European screening cohort, b predicting high-grade prostate cancer in 
the European screening cohort, c predicting any prostate cancer in the 
European clinical cohort, d predicting high-grade prostate cancer in 
the European clinical cohort, e predicting any prostate cancer in the 
Chinese clinical cohort, f predicting high-grade prostate cancer in the 
Chinese clinical cohort. The yellow line is for A-ERSPC-RC3 and the 
black line is  for the CPCC-RC. PCa prostate cancer, HGPCa high-
grade prostate cancer
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differences between a population-based screening setting 
as compared to a referral population [17]. In addition, the 
number of cores, age and the PSA levels differ between the 
cohort on which the A-ERSPC-RC was updated (Hong Kong 
origin). These differences could explain the underestima-
tion of the A-ERSPC-RC. In comparison with the origi-
nal ERSPC-RC, Zhu, et al. found that it overestimated the 
probability of PCa and HGPCa by approximately 20% [9]. 
Yoon et al. validated the ERSPC-RC in a Korean cohort and 
showed the predicted probabilities were nearly 20% higher 
than the actual rate [8]. The over-estimation of the origi-
nal ERSPC-RC and under-estimation of the A-ERSPC-RC 
indicates that the A-ERSPC-RC could need a more region-
specific adaptation or addition of other relevant predictors, 
e.g. age. When evaluating RCs in other settings, the risk fac-
tors distribution in relation to the outcome should be taken 
into consideration: i.e. the case mix of a cohort. This could 
explain the differences in the predictive performance of the 
tested RCs. For example, the PSA-PCa ratio might contrib-
ute to a good predictive capability in the Chinese cohort and 
the European screening cohort, while it could be the reason 
for a poor prediction in the EU clinical cohorts.
For the CPCC-RC, the predictive performance was good 
in the independent Chinese cohort as well as in the European 
screening cohort, but not in the European clinical cohort. 
This suggests that the CPCC-RC is applicable outside its 
development setting in Asia, but as expected less suitable in 
the European clinical setting with in general a higher preva-
lence of PCa and significant PCa. This observation is con-
firmed by Ankerts et al. in where an internationally validated 
risk calculator for patients in North America and Europe was 
developed [17]. They found a substantial deviation between 
Fig. 2  Decision curve analysis for a any prostate cancer in the Euro-
pean screening cohort, b high-grade prostate cancer in the European 
screening cohort, c any prostate cancer in the European clinical 
cohort, d high-grade prostate cancer in the European clinical cohort, 
e predicting any prostate cancer in the Chinese clinical cohort, f high-
grade prostate cancer in the Chinese clinical cohort. The yellow line 
is  for A-ERSPC-RC3 and the black line is  for the CPCC-RC. PCa 
prostate cancer, HGPCa high-grade prostate cancer
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the predicted risk and the actual risk when applying the 
Prostate Cancer Prevention Trial risk calculator (developed 
in the US) to data from European centers. Using the data 
from eight North American medical centers, a new compre-
hensive risk prediction model was established and validated 
in three European centers. Less deviation was found with 
the newly developed Prostate Biopsy Collaborative Group 
model. Although they did not look at predictive performance 
in an Asian cohort, the message was similar to ours: exter-
nal validation and recalibration are necessary before imple-
menting RCs in daily clinical practice. Similarly, this study 
indicated the inapplicability of a European risk calculator 
in an Asian population. The CPCC-RC has shown to be 
well-calibrated in an East Asian population [10]. There are 
several other RCs in East Asian populations, such as Chi-
nese [18], Korean [19, 20], and Japanese RCs [21]. Head-to-
head comparison is required to compare these several RCs 
in clinical utility.
Development of numerous RCs is not helping the imple-
mentation of these useful tools. Instead, adapting existing 
RCs known to have good discriminative capability or con-
structing an internationally based risk calculator taking into 
account of ethnicity and heterogeneity between populations 
would be the way to go to optimize prostate cancer predic-
tion on biopsy worldwide. The additional benefit of an inter-
national risk calculator would be a uniform patient selection 
for PCa, making it easier to compare study outcomes. In 
addition, existing and externally validated (international) 
RCs must be constantly updated with new findings that 
potentially can improve predictive capability. Multipara-
metric magnetic resonance imagining and novel biomark-
ers as four kallikrein, Prostate Cancer Antigen (PCA3) and 
Prostate Health Index (PHI) are promising additions in RCs 
that are used to select men with an elevated risk of having 
HGPCa and should be incorporated in multivariable pre-
diction tools to analyze their potential improvement of the 
clinical utility [22, 23]. Importantly, MRI has evolved as 
a powerful test in the diagnostic situation [24], which has 
been recommended by the latest EAU guidelines for initial 
biopsy setting.
There are several limitations to our study. First, currently, 
ISUP classification was adopted in the assessment of risk 
for PCa RCs just as our previous studies which incorporate 
ISUP classifications [7], however, we did not apply ISUP 
standards due to the lack of the detailed Gleason scores. 
Further validation of ISUP classifications should be applied. 
Second, the three cohorts of patients differ in testing meth-
odology, mainly in the nature of the participants and the 
indication for biopsy. It is important to note that the Chinese 
cohort is limited to men referred for a prostate cancer evalu-
ation and do not reflect the general (screening) population, 
thus there is sensible risk of selection in the clinical cohort. 
Furthermore, the design to external validation of the RCs is 
retrospective; however, the data is prospectively collected for 
Table 3  Biopsy reduction, delayed prostate cancers diagnosis and net 
true positives using the Chinese Prostate Cancer Consortium Risk 
Calculator and the Asian adapted Rotterdam European Randomized 
Study of Screening for Prostate Cancer Risk Calculator 3 compared 
to biopsy all in 1000 Chinese men
CPCC-RC Chinese Prostate Cancer Consortium Risk Calculator, A-ERSPC-RC3 Asian adapted Rotterdam European Randomized Study of 
Screening for Prostate Cancer Risk Calculator 3
Threshold Number of biopsies Number of indolent cancers Number of high-grade cancers Additional net true 
reduction of biopsies 
compared to ERSPC 
strategy
Clinical significant 
PCa
(A) Performed (B) 
Reduced (% 
total A)
(C) Detected (% A) (D) Not 
detected 
(% B)
(E) Detected (% A) (F) Missed 
diagnosis 
(% B)
(G) × 1000 men
Biopsy all 1000 0 342 0 239 (24) 0
5%
 CPCC-RC 900 100 (10) 330 (37) 12 (12) 231 (26) 8 (8) 0.7
 A-ERSPC-RC3 873 127 (13) 335 (38) 7 (6) 229 (26) 10 (8) –
10%
 CPCC-RC 752 248 (25) 310 (41) 32 (13) 220 (29) 19 (8) 6.8
 A-ERSPC-RC3 725 275 (28) 325 (45) 17 (6) 211 (29) 28 (10) –
15%
 CPCC-RC 612 388 (39) 285 (47) 57 (15) 202 (33) 37 (10) 7.4
 A-ERSPC-RC3 604 396 (40) 313 (52) 29 (7) 194 (32) 45 (11) –
20%
 CPCC-RC 512 488 (49) 258 (50) 84 (17) 184 (36) 55 (11) 3.9
 A-ERSPC-RC3 515 485 (49) 295 (57) 47 (10) 182 (35) 57 (12) –
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the European screening cohort. In the Chinese cohort there 
were some missing variables, but due to imputation could 
still be used for analysis. In general, it has been shown in 
many studies that instead of using a PSA cut-off for patient 
selection risk calculators should be used, as these tools can 
reduce one-third of the unnecessary biopsies [7].
Conclusion
The Asian-adapted ERSPC-RC3 performed well in a con-
temporary Chinese multi-center clinical cohort. The CPCC-
RC performed well in a European PSA based screening 
setting, but less in a multi-center European clinical cohort. 
Both RCs reduce unnecessary biopsies compared to a PSA-
decision-based strategy. External validation and calibration 
are very necessary before implementing RCs.
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